The present state of antineoplaston research (1)

Integr Cancer Ther. 2004 Mar;3(1):47-58. doi: 10.1177/1534735403261964.


Antineoplastons work as molecular switches, which regulate expression of genes p53 and p21 through demethylation of promoter sequences and acetylation of histones. They also inhibit the uptake of growth-critical amino acids, such as 1-glutamine and 1-leucine in neoplastic cells. Phase II trials indicate efficacy of antineoplastons in low-grade glioma, brain stem glioma, high-grade glioma, adenocarcinoma of the colon, and hepatocellular carcinoma. The best results were observed in children with low-grade glioma, where 74% of patients obtained objective response, and in patients with adenocarcinoma of the colon with liver metastases whose survival rate of more than 5 years is 91% versus 39% in controls on chemotherapy. Gene array studies will explain antineoplaston-induced changes in gene expression.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Benzeneacetamides / pharmacology
  • Benzeneacetamides / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Child
  • Clinical Trials as Topic
  • Colonic Neoplasms / drug therapy*
  • Complementary Therapies*
  • Gene Expression Profiling
  • Gene Expression Regulation / drug effects*
  • Genes, p53
  • Glioma / drug therapy*
  • Humans
  • Piperidones / pharmacology
  • Piperidones / therapeutic use*
  • Survival Analysis


  • Benzeneacetamides
  • Piperidones